ciglitazone has been researched along with Cancer of Lung in 16 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciglitazone treatment suppressed COX-2 mRNA expression and COX-2 promoter activity while upregulating PPRE promoter activity." | 1.34 | Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells. ( Dubinett, SM; Hazra, S, 2007) |
| "When ciglitazone was added, the proliferation was observed by growth curve and the differentiation of cells was observed by flow cytometry, and the expression of cyclinD1 was observed by Western blot." | 1.32 | [The effects of nuclear factor kappa B decoy oligodeoxynucleotides on ciglitazone-induced differentiation of lung cancer cells A549]. ( Xu, YJ; Zhang, HL; Zhang, ZX, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, TW | 1 |
| Hong, DW | 1 |
| Park, JW | 1 |
| Hong, SH | 3 |
| Hann, SS | 1 |
| Tang, Q | 1 |
| Zheng, F | 1 |
| Zhao, S | 1 |
| Chen, J | 1 |
| Wang, Z | 1 |
| Yoshizaki, T | 1 |
| Motomura, W | 1 |
| Tanno, S | 2 |
| Kumei, S | 1 |
| Yoshizaki, Y | 1 |
| Okumura, T | 1 |
| Kim, BM | 1 |
| Maeng, K | 1 |
| Lee, KH | 1 |
| Wang, JJ | 1 |
| Mak, OT | 1 |
| Han, EJ | 1 |
| Im, CN | 1 |
| Park, SH | 1 |
| Moon, EY | 1 |
| James, SY | 1 |
| Lin, F | 1 |
| Kolluri, SK | 1 |
| Dawson, MI | 1 |
| Zhang, XK | 1 |
| Han, S | 2 |
| Sidell, N | 2 |
| Fisher, PB | 2 |
| Roman, J | 2 |
| Zhang, HL | 2 |
| Zhang, ZX | 2 |
| Xu, YJ | 2 |
| Allred, CD | 1 |
| Kilgore, MW | 1 |
| Avis, I | 1 |
| Martínez, A | 1 |
| Tauler, J | 1 |
| Zudaire, E | 1 |
| Mayburd, A | 1 |
| Abu-Ghazaleh, R | 1 |
| Ondrey, F | 1 |
| Mulshine, JL | 1 |
| Zhang, W | 1 |
| Zhang, H | 1 |
| Xing, L | 1 |
| Hazra, S | 1 |
| Dubinett, SM | 1 |
| Chang, TH | 1 |
| Szabo, E | 1 |
16 other studies available for ciglitazone and Cancer of Lung
| Article | Year |
|---|---|
CB11, a novel purine-based PPARɣ ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells.
Topics: 3T3 Cells; Adipocytes; Anilides; Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Azo Com | 2020 |
Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; AMP-Activated Protein Kinases; Apoptosis; Carcinoma, N | 2014 |
Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Culture Media; Humans; Hypogly | 2010 |
Combined treatment with the Cox-2 inhibitor niflumic acid and PPARγ ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 8; Cell Line, | 2011 |
Induction of apoptosis by 15d-PGJ2 via ROS formation: an alternative pathway without PPARγ activation in non-small cell lung carcinoma A549 cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Glutathione; Humans; Lung Neo | 2011 |
Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARγ-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 8; DNA Damage; Fluoresceins; Gamma Ray | 2013 |
Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.
Topics: Apoptosis; Benzoates; Breast Neoplasms; Cell Division; Female; Gene Expression Regulation, Neoplasti | 2003 |
Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells.
Topics: Apoptosis; Base Sequence; Cell Division; Cell Line, Tumor; DNA Primers; Gene Expression Regulation, | 2004 |
[The effects of nuclear factor kappa B decoy oligodeoxynucleotides on ciglitazone-induced differentiation of lung cancer cells A549].
Topics: Cell Cycle; Cell Differentiation; Cell Line, Tumor; Genes, MDR; Humans; Lung Neoplasms; NF-kappa B; | 2004 |
Ligands of peroxisome proliferator-activated receptor gamma inhibit lung cancer cell growth and induce apoptosis by stimulation of P21 expression.
Topics: Antineoplastic Agents; Apoptosis; Chromans; Cyclin D1; Humans; Lung Neoplasms; Prostaglandin D2; Pro | 2004 |
[Ciglitazone inhibits growth of lung cancer cells A549 in vitro and in vivo: an experimental study].
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kin | 2004 |
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
Topics: Alitretinoin; Anilides; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Female; | 2005 |
Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arachidonic Acid; Caspases | 2005 |
Influence of ciglitazone on A549 cells growth in vitro and in vivo and mechanism.
Topics: Animals; Cell Proliferation; Cyclin D1; Humans; Lung Neoplasms; Mice; Mice, Nude; PPAR gamma; Random | 2006 |
Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Humans; Hydroxypro | 2007 |
Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Blotting, Western; Carc | 2002 |